Biotechnology Daily
more-
Ionis and UCSD take an antisense approach to fighting treatment-resistant multiple myeloma
Ionis’ antisense oligonucleotide technology forms the backbone of three drugs to treat rare diseases. Now,…
Market Watch
more-
U.S. stocks finish at fresh highs as Biden begins presidency with vow of unity
Dow, S&P 500 and Nasdaq set closing records
Bio Business News
more
In vitro test maker Ortho Clinical Diagnostics files $1.5B Nasdaq IPO
Ortho Clinical Diagnostics is hoping to pay down a large…
GSK, German Merck’s $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer
A drug that Pfizer passed over but saw a revitalized…
Biden and biotech: Science first
The November election now seems such a long time ago:…
World News
more
Equifax stock surges toward biggest gain in 12 years after ‘impressive’ business update
Shares of Equifax Inc. EFX, +7.84% shot up 9.3% into…
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Facebook video calls soar 1000% during Italy’s lockdown
Facebook has seen usage across its platforms surge in countries…
Ionis and UCSD take an antisense approach to fighting treatment-resistant multiple myeloma
Roller coaster ride for Verastem continues as 2 weeks into the job, its CMO quits
Haemonetics to buy bloodstopper medtech Cardiva Medical in $510M deal
Turnstone buys Myst to add tumor-infiltrating lymphocyte assets
In vitro test maker Ortho Clinical Diagnostics files $1.5B Nasdaq IPO
GSK, German Merck’s $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer
Biden and biotech: Science first
Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer
U.S. stocks finish at fresh highs as Biden begins presidency with vow of unity
DraftKings stock rallies after Morgan Stanley turns bullish